Chitra R Natalie

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials

Andrew Blauvelt, Jacob P. Thyssen, Emma Guttman‐Yassky et al. · British Journal of Dermatology · 2023 · 149 citations · Full text

Medicine, Dermatology, Pharmacology +17

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis

Eric L. Simpson, Melinda Gooderham, Andreas Wollenberg et al. · JAMA Dermatology · 2023 · 143 citations · Full text

Medicine, Dermatology, Pharmacotherapy +17

Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure

Kevin R. Murphy, Bradley E. Chipps, David A. Beuther et al. · The Journal of Allergy and Clinical Immunology In Practice · 2020 · 73 citations

Medicine, Preventive Medicine, Health Assessment +8

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials

Linda Stein Gold, Diamant Thaçi, Jacob P. Thyssen et al. · American Journal of Clinical Dermatology · 2023 · 67 citations · Full text

Life Sciences, Dermatology, Immunology +17

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

Amy S. Paller, Carsten Flohr, Lawrence F. Eichenfield et al. · Dermatology and Therapy · 2023 · 44 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16